Retatrutide Delivers Substantial Weight Loss in Type 2 Diabetes

Boehringer Ingelheim announced promising findings from the Phase III SYNCHRONIZE-2 trial, which evaluated the glucagon/GLP-1 receptor dual agonist survodutide (BI 456906) in adults with obesity or overweight and type 2 diabetes (T2D). The trial met its primary endpoints of body weight change from baseline and a 5% or greater body weight reduction from baseline for both the treatment group and efficacy estimands.

After 76 weeks of treatment, the average weight loss in the survodutide group was 13.1%, significantly higher than the 3.1% loss observed in the placebo group (p < 0.0001). Additionally, 79.3% of those treated with survodutide achieved a body weight reduction of 5% or more, compared to 32.7% in the placebo group (p < 0.0001). The results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) and published simultaneously in The New England Journal of Medicine.